Table 1 Summary of all studies measuring multiple aeroallergen SPT in subjects with CSU
Reference (author, year) | Country | Definition of CSU in weeks | Number of inhalant allergens tested | Number of CSU subjects undergoing SPT | % of positive SPT for aeroallergens in CSU patients | Number of healthy controls undergoing SPT | % of positive SPT for aeroallergens in controls | Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days | % of CSU subjects with atopic diseases: allergic rhinitis (AR) and/or asthma (A) | Total IgE levels in CSU subjects |
|---|---|---|---|---|---|---|---|---|---|---|
Sibbald, 1991 [53] | Canada | – | 12 | 75 | 46 | – | – | – | 10 (A) | 23% > 200 IU/L |
Liutu, 1998 [54] | Finland | > 8 | ≥ 4 | 91 | 23.1 | – | – | – | – | 49.3% > 111 IU/L |
Caliskaner, 2004 [51] | Turkey | > 6 | 56 | 259 | 27.4 | 300 | 7 | 7 (AH) | Excluded AR/A | – |
Ilonidis, 2005 [55] | Greece | – | 8 | 130 | 15.4 | – | – | – | – | – |
Kulthanan, 2008 [56] | Thailand | > 6 | 12 | 88 | 41 | – | – | 3 (AH) 28 (SC) | 20.5 (AR) 6.8 (A) | – |
Ye, 2008 [57] | Korea | > 6 | 50 | 174 | 58.0 | 79 | 30.4 | 3 (AH) 3 (SC) | 36.1 (AR) 7.7 (A) | – |
Daschner, 2010 [58] | Spain | – | 10 | 80 | 45 | 522 (with AR/A) | – | – |  |  |
Refaat, 2010 [59] | Egypt | – | 9 | 174 | 17.2 | 200 | 3.5 | 5 (AH) | Excluded AR/A | – |
Green, 2014 [60] | Canada | – | 30 | 44 | 31.8 | – | – | – | – | – |
Bains, 2015 [52] | India | – | 66 | 41 | 56.1 | – | – | 3 (AH) 14 (SC) | Excluded AR/A | – |
Oncham, 2018 [61] | Thailand | – | 17 | 140 | 57.4 | – | – | – | – | – |
Bilgir, 2019 [62] | Turkey | > 6 | – | 302 | 55 | – | – | – | – | – |
Nath, 2007 [19] | India | > 6 | 11 | 50 | ≥ 24 | – | – | – | – | – |
De Vos, 2012 [12] | United States | > 6 | 22 | 19 | ≥ 44 | 19 | ≥26 | – | Excluded AR | – |
Parasuramalu, 2014 [20] | India | > 6 | 26 | 300 |  1 | – | – | 15 (AH) | 11.3 (AR) 2.3 (A) | – |
India | > 6 | 40 | 56 | ≥ 42.9 | – | – | 2 (AH) 14 (SC) | – | – |